ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2019 and some content may be unavailable. To unlock all content for 2019, please visit the archives.

Abstract: TH-PO781

Mortality in Children with ESRD: A Guatemalan Retrospective Cohort Study

Session Information

  • Pediatric CKD
    November 07, 2019 | Location: Exhibit Hall, Walter E. Washington Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Pediatric Nephrology

  • 1700 Pediatric Nephrology

Authors

  • Morales, Josue Abraham, Universidad de San Carlos, Guatemala, Guatemala
  • Aguilar, Angie Lizet, Fundanier, Guatemala, Guatemala
  • Lou-Meda, Randall M., Fundanier, Guatemala, Guatemala
  • Almorza, Larissa María, Universidad de San Carlos, Guatemala, Guatemala
Background

Mortality rates and long-term survival data in ESRD children are sparse although different modalities of RRT have been used during decades
We evaluate the mortality overtime in a tertiary hospital in Guatemala

Methods

After ethics approval, we performed a single center retrospective cohort study of all patients with ESRD younger than 18 years, between Jan2015 and Dec2017
Mortality rate was expressed as number of deaths/1000patients
Mortality incidence rate, expressed as number of deaths/100patient-years was determined by, sex, RRT and age
Long-term survival rates were calculated by Kaplan Meier test and significant confirm by Log Rank and Breslow tests

Results

A total of 370 charts were reviewed. Of those, 115 were from PD, 221 from HD and 34 from transplant. During the study period 25 patients died. Of those, 52%(13/25) were female, the mean age was 12.7yr(SD 3.4), 72%(18/25) were from HD and the rest from PD(7/25). No deaths from transplanted patients were reported during the study. The mortality rate in 2015, 2016 and 2017 were 50, 50 and 32/1000patients. The mortality incidence rate was 8.20/100patient-years. No difference in mortality incidence rate was found by sex (fem 8/100patient-years, masc 8.4/100patient-years). The highest incidence of mortality rate was found in the HD and in the 5-9 age group (17.35/100patient-years, 20/100patient-years). When analyzing long-term survival rates using Kaplan Meier, the overall mortality rate at 3 years was 20%; no significant difference was identified by sex (p, 0.509) nevertheless; a significant difference was found between HD(38%) and PD(16%), p, 0.001. Regarding age, no significant difference in mortality rate between the 5-9, 10-14 and 15-18 age groups was identified at 2 years (25%,15%,10%), (p, 0.174)

Conclusion

In our study, the overall mortality incidence rate was higher than reported in literature
Mortality rate, incidence mortality rate and long-term survival were similar between the sexes. Among age, the 5-9 years group demonstrated the highest mortality rates
Regarding RRT, the incidence mortality rates in PD is comparable with literature; however, our HD mortality rates are 4 times higher than what has patient-years
Increasing the proportion of children treated with renal transplantation and PD rather than HD can improve survival further and costs in our centre